Literature DB >> 25638459

Characterization of variegate porphyria mutations using a minigene approach.

Barbara Xoana Granata1, Marco Baralle, Laura De Conti, Victoria Parera, Maria Victoria Rossetti.   

Abstract

Porphyrias are a group of metabolic diseases that affect the skin and/or nervous system. In 2008, three unrelated patients were diagnosed with variegate porphyria at the CIPYP (Centro de Investigaciones sobre Porfirinas y Porfirias). Sequencing of the protoporphyrinogen oxidase gene, the gene altered in this type of porphyria, revealed three previously undescribed mutations: c.338+3insT, c.807G>A, and c.808-1G>C. As these mutations do not affect the protein sequence, we hypothesized that they might be splicing mutations. RT-PCRs performed on the patient's mRNAs showed normal mRNA or no amplification at all. This result indicated that the aberrant spliced transcript is possibly being degraded. In order to establish whether they were responsible or not for the patient's disease by causing aberrant splicing, we utilized a minigene approach. We found that the three mutations lead to exon skipping; therefore, the abnormal mRNAs are most likely degraded by a mechanism such as nonsense-mediated decay. In conclusion, these mutations are responsible for the disease because they alter the normal splicing pathway, thus providing a functional explanation for the appearance of disease and highlighting the use of minigene assays to complement transcript analysis.

Entities:  

Year:  2015        PMID: 25638459      PMCID: PMC4375119          DOI: 10.1007/8904_2014_388

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  27 in total

1.  Homozygous variegate porphyria: 20 y follow-up and characterization of molecular defect.

Authors:  R Kauppinen; K Timonen; M von und zu Fraunberg; E Laitinen; H Ahola; R Tenhunen; S Taketani; P Mustajoki
Journal:  J Invest Dermatol       Date:  2001-04       Impact factor: 8.551

2.  Predictive identification of exonic splicing enhancers in human genes.

Authors:  William G Fairbrother; Ru-Fang Yeh; Phillip A Sharp; Christopher B Burge
Journal:  Science       Date:  2002-07-11       Impact factor: 47.728

Review 3.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics.

Authors:  Lynne E Maquat
Journal:  Nat Rev Mol Cell Biol       Date:  2004-02       Impact factor: 94.444

4.  A Chilean boy with severe photosensitivity and finger shortening: the first case of homozygous variegate porphyria in South America.

Authors:  P Poblete-Gutiérrez; C Wolff; R Farias; J Frank
Journal:  Br J Dermatol       Date:  2006-02       Impact factor: 9.302

Review 5.  Missed threads. The impact of pre-mRNA splicing defects on clinical practice.

Authors:  Diana Baralle; Anneke Lucassen; Emanuele Buratti
Journal:  EMBO Rep       Date:  2009-08       Impact factor: 8.807

Review 6.  Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband.

Authors:  J Frank; J McGrath; H Lam; R M Graham; J L Hawk; A M Christiano
Journal:  J Invest Dermatol       Date:  1998-04       Impact factor: 8.551

7.  Improved splice site detection in Genie.

Authors:  M G Reese; F H Eeckman; D Kulp; D Haussler
Journal:  J Comput Biol       Date:  1997       Impact factor: 1.479

Review 8.  Homozygous variegate porphyria: an evolving clinical syndrome.

Authors:  R J Hift; P N Meissner; G Todd; P Kirby; D Bilsland; P Collins; J Ferguson; M R Moore
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

9.  Homozygous variegate porphyria: a compound heterozygote with novel mutations in the protoporphyrinogen oxidase gene.

Authors:  R A Palmer; G H Elder; D F Barrett; S G Keohane
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

10.  Molecular characterization of homozygous variegate porphyria.

Authors:  A G Roberts; H Puy; T A Dailey; R R Morgan; S D Whatley; H A Dailey; P Martasek; Y Nordmann; J C Deybach; G H Elder
Journal:  Hum Mol Genet       Date:  1998-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.